Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRichard Chen, PA
Clinical InstructorAbout
Research
Publications
2026
Mutational patterns in a large cohort of parathyroid carcinomas
Pandya C, Uzilov A, Costa-Guda J, Bellizzi J, Taik P, Moe A, Strahl M, van der Tuin K, Stevenson M, Cavaco B, Cetani F, Marcocci C, Karhu A, Arola J, Schalin-Jäntti C, Morreau H, Thakker R, Schadt E, Sebra R, Li S, Chen R, Arnold A. Mutational patterns in a large cohort of parathyroid carcinomas. Journal Of Endocrinological Investigation 2026, 1-11. PMID: 41879893, DOI: 10.1007/s40618-026-02855-x.Peer-Reviewed Original ResearchParathyroid carcinomaCDC73 mutationsEvaluating patientsSporadic parathyroid carcinomaGermline pathogenic variantsGenotype-phenotype correlationCDC73 geneRecurrent/metastatic diseaseRare malignancyCarcinoma cohortNext-generation DNA sequencingWHO criteriaTargeted therapyClinical featuresTumor typesOncogenic driversPathogenic variantsCarcinomaDriver mutationsPatientsMutation patternsPI3K/mTOR activationIndividualized treatmentCohortPI3K/AKT/mTOR pathwayMonitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
Nixon A, Navarro F, Zhou K, Abbott C, McDaniel L, Ravi N, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Strickler J, Boyle S, Chen R, Uronis H. Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. Scientific Reports 2026 PMID: 41872254, DOI: 10.1038/s41598-026-43178-4.Peer-Reviewed Original ResearchMetastatic esophagogastric cancerProgression-free survivalOverall survivalTreatment responseAssociated with worse OSAssociated with worse overall survivalDetection of disease progressionPrediction of treatment responsePhase II trialLiquid biopsy approachMonitoring Treatment ResponseEsophagogastric cancer patientsMedian lead timeLiquid biopsy platformTreatment decision-makingCtDNA dynamicsCtDNA assaysCtDNA levelsII trialTumor sizeBiopsy approachTumor DNAEsophagogastric cancerBiopsy platformTumor samplesThe Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Hunter N, Parsons H, Cope L, Canzoniero J, Navarro F, El-Refai S, Anampa J, Sparano J, Rimawi M, Storniolo A, Mainor C, Nanda R, DeMichele A, Gupta G, Stringer-Reasor E, Lynce F, Cobain E, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang E, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow J, Chen R, Boyle S, Stearns V, Wolff A, Park B. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. Journal Of Clinical Oncology 2026, jco2502934. PMID: 41805422, DOI: 10.1200/jco-25-02934.Peer-Reviewed Original ResearchInvasive disease-free survivalTriple-negative breast cancerPathological complete responseCirculating tumor DNAMinimal residual diseaseDetect circulating tumor DNAPathological response evaluationNon-pCR patientsNeoadjuvant therapyNegative predictive valueTumor DNANon-pCRCtDNA-negativeResidual diseaseBreast cancerHuman epidermal growth factor receptor 2 (HER2)-positiveTNBC cohortHER2-positive breast cancerBiomarkers of treatment responseResponse evaluationTherapeutic de-escalationSecondary objectivesDisease-free survivalSuperior risk stratificationLong-term survivalUse of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.
do Amaral P, Zerey M, Schaffer K, Moses K, Chen Y, Abbott C, Chen R, Rini B, Tan A. Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings. Journal Of Clinical Oncology 2026, 44: 516-516. DOI: 10.1200/jco.2026.44.7_suppl.516.Peer-Reviewed Original ResearchLocalized Renal Cell CarcinomaCirculating tumor DNARenal cell carcinomaUndetectable circulating tumour DNAMolecular residual diseasePrognostic valueRecurrence rateFollow-upSingle-center retrospective cohort studyCirculating tumor DNA assessmentsCirculating tumor DNA shedCirculating tumor DNA statusCirculating tumor DNA testingCtDNA positivityCirculating tumor DNA detectionRenal cell carcinoma patientsMedian Follow-UpWhole-genome sequencingMultiple solid tumorsRetrospective cohort studyPatient-specific variantsPT3 diseaseRadical nephrectomyRadiographic recurrenceResidual diseaseUltrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer
Nishizaki D, Law A, Li B, Abbott C, Chen Y, Lee S, Pyke R, Keough K, Daniels G, Yeung K, Boyle S, Chen R, Kato S. Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer. Npj Precision Oncology 2026, 10: 79. PMID: 41580469, PMCID: PMC12936199, DOI: 10.1038/s41698-026-01287-3.Peer-Reviewed Original ResearchProgression-free survivalMolecular complete responseImmune checkpoint inhibitorsCtDNA monitoringPrognostic of progression-free survivalPredictor of immunotherapy responseLongitudinal plasma samplesEarly molecular responseBaseline to first follow-upCtDNA clearanceFirst follow-upCheckpoint inhibitorsComplete responseCtDNA assaysICI responseOverall survivalImmunotherapy responseResponse assessmentAdvanced/metastatic cancerClinical decision-makingFollow-upSomatic mutationsAdvanced cancerPlasma samplesPatients
2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cárdenas A, Keough K, Galvao V, Alonso G, Olano A, Villar M, Oberoi A, Bardaji J, Hernando-Calvo A, Braña I, Pretelli G, Ortega B, Arenillas C, Czerniak N, Navarro F, Li B, Pyke R, Ravi N, Zatse C, Grussu F, Sanz M, Viaplana C, Raskina K, Jimenez J, Fasani R, Casbas-Hernandez P, Oflazoglu E, Hodgson D, Reis-Filho J, Felip E, Élez E, Muñoz E, Dienstmann R, Tabernero J, Lopez-Perez R, Nuciforo P, Chen R, Boyle S, Toledo R. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clinical Cancer Research 2025, 32: 333-349. PMID: 41400436, PMCID: PMC12809116, DOI: 10.1158/1078-0432.ccr-25-2312.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitorsCtDNA dynamicsProgression-FreeOverall survivalCancer treated with immunotherapyTumor-specific mutationsCohort of patientsProspective validation cohortImmune cell engagementBiomarker potentialCtDNA clearanceImmunotherapy modalitiesRadiological responseProlonged survivalCtDNA detectionTreatment initiationTrue progressionRetrospective cohortValidation cohortCell engagementImmunotherapyBispecific antibodiesCancer typesPatientsLongitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
Black J, Karasaki T, Abbott C, Li B, Veeriah S, Al Bakir M, Liu K, Huebner A, Martínez-Ruiz C, Pawlik P, Moore D, Marinelli D, Shutkever O, Murphy C, Liu L, Grieco C, Grimes K, Navarro F, Pyke R, Bartha G, Keough K, Dea S, Ravi N, Lyle J, Harris J, Brown K, Blackhall F, Hassani F, Fennell D, McGranahan N, Shaw J, Abbosh C, Consortium T, Hackshaw A, Jamal-Hanjani M, Frankell A, Boyle S, Chen R, Swanton C. Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. Cell 2025, 188: 7083-7098.e18. PMID: 41205598, DOI: 10.1016/j.cell.2025.10.020.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCirculating tumor DNACtDNA detectionEarly stage NSCLCStage non-small cell lung cancerCtDNA kineticsPattern of relapseIntermediate risk groupCell lung cancerLung cancer risk predictionAnatomical patternsCancer risk predictionCtDNA monitoringCtDNA statusAdjuvant therapyTumor DNAPrognostic assessmentLung cancerDisease stratificationRisk groupsTherapeutic strategiesTreatment recommendationsClinical utilityPlasma samplesPatient outcomesUltrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer.
Nishizaki D, Law A, Abbott C, Chen Y, Li B, Lee S, Daniels G, Yeung K, Boyle S, Chen R, Kato S. Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer. Journal Of Clinical Oncology 2025, 43: 2561-2561. DOI: 10.1200/jco.2025.43.16_suppl.2561.Peer-Reviewed Original ResearchCirculating tumor DNAProgression-free survivalImmune checkpoint inhibitionCtDNA monitoringTumor DNAPredictors of progression-free survivalCtDNA-based liquid biopsiesMinimal residual disease assessmentCirculating tumor DNA levelsImmune checkpoint inhibition therapyMolecular complete responseYear PFS ratesPlasma samplesProgression-free statusResidual disease assessmentLiquid biopsy approachLongitudinal plasma samplesPrediction of therapeutic outcomeEarly molecular responseEvaluation of immunotherapy responseEarly prediction of therapeutic outcomesBaseline to first follow-upCtDNA kineticsFirst follow-upImmunotherapy successUltrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Cabel L, Lamy C, Keough K, Abbott C, Pouget N, Pierga J, Sablin M, Flavius J, Bronzini T, Laas E, Darrigues L, Feron J, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle S, Chen R, Le Tourneau C, Bidard F. Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2025, 43: 552-552. DOI: 10.1200/jco.2025.43.16_suppl.552.Peer-Reviewed Original ResearchTriple-negative breast cancerPathological complete responsePost-NACCtDNA detectionFollow-upPlasma ctDNADistant metastasisDistant relapse-free intervalPathological complete response statusPatients treated with NACTriple-negative breast cancer patientsEarly-stage TNBC patientsPost-surgical follow-upCtDNA-negative patientsCtDNA-positive patientsPost-neoadjuvant chemotherapyResidual disease levelsStratify survival outcomesImmune checkpoint inhibitorsNon-relapsing patientsRelapse-free intervalAdjuvant treatment decisionsMedian Follow-UpTumor-specific variantsMultivariate Cox modelClinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, Howes T, Shotts K, Densmore J, Spasic M, Da Silva D, Chen R, Lata J, Skolnik J, Keler T, Yellin M, LaVallee T, Fairchild J, Boffo S, O’Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi S, Fong L. Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 2025, 31: 1463-1475. PMID: 39964352, PMCID: PMC11995007, DOI: 10.1158/1078-0432.ccr-24-3693.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerPoly-ICLCAdverse eventsGrade 3 to 4 treatment-related adverse eventsAssociated with clinical benefitAssociated with disease controlResponse rateDisease control rateProgression-free survivalImmune checkpoint therapyComposite response rateCycles 1 to 3Disease controlCDX-301Combination immunotherapyCombined radiotherapyCheckpoint therapyImmunotherapy efficacyOverall survivalOpen-labelPrimary endpointSecondary endpointsCohort B